Innovent Biologics May See Stronger Commercial Outlook -- Market Talk

Dow Jones

07/08

0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

July 08, 2025 00:56 ET (04:56 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2549959430"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549959430\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549959430?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 12:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549959430","market":"us","top_or_hot":-1,"title":"Innovent Biologics May See Stronger Commercial Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics May See Stronger Commercial Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics May See Stronger Commercial Outlook -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-08 12:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSBA.UK","symbol_name":"汇丰控股有限公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2549959430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549959430","pubTimestamp":1751950560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSBA.UK":"汇丰控股有限公司","BK1161":"生物科技","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK1610":"ETF&股票定投概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1601":"香港本地股","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","HSHD.SI":"HSBC HK SDR 5to1","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","BK1583":"高瓴概念","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK1231":"综合性银行","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK4588":"碎股","03143":"华夏香港银行股","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4521":"英国银行股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","HSBC":"汇丰","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","BK1572":"香港银行股","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","BK1589":"北水核心资产","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","01801":"信达生物","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","00005":"汇丰控股","BK4585":"ETF&股票定投概念","BK4207":"综合性银行"},"translate_title":"信达生物可能会看到更强劲的商业前景——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.9,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.6,"HSHD.SI":0.6},"content_text":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 00:56 ET (04:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}